Compound News and Research

RSS

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

US market for orthopedic extremity devices to grow at 10% CAGR to $4.6 billion by 2015

According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.

18 Jan 2011

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

BPA more harmful to women with hormonal and fertility imbalances

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.

13 Jan 2011

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

The Scripps Research Institute and the University of Pennsylvania School of Medicine have been awarded approximately $8.2 million over five years to develop novel compounds that could eventually become drug candidates for the treatment of tobacco addiction. Of the funds awarded, $5.7 million will go to Scripps Research, and $2.5 million to the University of Pennsylvania.

12 Jan 2011

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

AstraZeneca and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

12 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Resveratrol stimulates expression of adiponectin hormone: Study

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

10 Jan 2011

Positive PK study results from ECLIPSE trial against cardiovascular disease

Omthera Pharmaceuticals, a privately-held emerging specialty pharmaceuticals company, today announced data from its ECLIPSE trial, designed to evaluate the bioavailability of Epanova™, the Company's lead compound for the treatment of very high triglycerides, in comparison to Lovaza®, the leading prescription Omega 3.

10 Jan 2011

Curis announces selection of CUDC-907 as development candidate for cancer

Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.

7 Jan 2011

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Amgen and Xencor, announced today that they will collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.

7 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Tomatoes contain nutrient which prevents vascular diseases

They are the most widely produced fruit in the world and now scientists in Japan have discovered that tomatoes contain a nutrient which could tackle the onset of vascular diseases. The research, published in the journal Molecular Nutrition & Food Research, reveals that an extracted compound, 9-oxo-octadecadienoic, has anti-dyslipidemic affects.

6 Jan 2011

Research: Tomatoes can tackle onset of vascular diseases

They are the most widely produced fruit in the world and now scientists in Japan have discovered that tomatoes contain a nutrient which could tackle the onset of vascular diseases.

6 Jan 2011

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.

6 Jan 2011

Compound News and Research

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Seordus recieves Japanese patent for SER100

US market for orthopedic extremity devices to grow at 10% CAGR to $4.6 billion by 2015

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

BPA more harmful to women with hormonal and fertility imbalances

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Resveratrol stimulates expression of adiponectin hormone: Study

Positive PK study results from ECLIPSE trial against cardiovascular disease

Curis announces selection of CUDC-907 as development candidate for cancer

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Tomatoes contain nutrient which prevents vascular diseases

Research: Tomatoes can tackle onset of vascular diseases

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News